RxDoctor Payments Data

Gerard D Aversa, MD

Ophthalmology · Valley Stream, NYNPI 1548265523

Payments from drug & device makers

$107,831in general payments, 2019–2025

Across 429 payments — averaging $251.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$40K
  • AbbVie$36K
  • Kala Pharmaceuticals, Inc.$17K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$4K
  • Glaukos Corporation$2K
  • Alcon Research LLC$2K
  • plus $8K from 19 others

What the payments were for

  • Consulting fees$9,6759%
  • Speaking & faculty fees$83,52577%
  • Travel & lodging$3,2953%
  • Food & beverage$11,23810%
  • Education$980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$107,831 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$748,455
Medicare patients
1,746
Services billed
5,428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine328$429,304
OxervateCenegermin-Bkbj12$341,287
XiidraLifitegrast135$189,984
MieboPerfluorohexyloctane/Pf119$99,660
ProlensaBromfenac Sodium230$77,841
Cyclosporine100$63,221
LumiganBimatoprost97$62,617
InveltysLoteprednol Etabonate177$50,163
XdemvyLotilaner16$28,905
CombiganBrimonidine Tartrate/Timolol56$19,502
Prednisolone Acetate529$16,870
Brimonidine Tartrate138$16,298
Travoprost65$14,531
TyrvayaVarenicline Tartrate19$12,370
Alphagan PBrimonidine Tartrate23$10,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$35,922$521,768504 claims
Dompe US, Inc.Oxervate$473$341,28712 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$40,390$289,644254 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax, Besivance$3,534$96,286308 claims
Kala Pharmaceuticals, Inc.Inveltys$16,707$50,163177 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$361$28,90516 claims
Oyster Point Pharma, Inc.Tyrvaya$410$12,37019 claims
NovartisIlevro$1,315$4,33712 claims
AlconSimbrinza$477$3,47911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Valley Stream

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →